-
Mashup Score: 0COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy - 7 month(s) ago
More than 3 years have passed since Coronavirus disease 2019 (COVID-19) was declared a global pandemic, yet COVID-19 still severely impacts immunocompromised individuals including those treated with…
Source: onlinelibrary.wiley.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 12Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial - 8 month(s) ago
Nature Medicine – Second-line treatment with axicabtagene ciloleucel, a CD19-targeting CAR-T cell therapy, resulted in high response rates and durable remissions in patients with high-risk large B…
Source: www.nature.comCategories: Hematologists1, Latest HeadlinesTweet-
✨New in @NatureMedicine! 2nd line treatment with axi-cel #CARTcells resulted in high response rates and durable remissions in patients with transplant-ineligible large B-cell lymphoma. Kudos to @HouotRoch, @BachyEmmanuel, and the @LysaLymphoma team!👏 https://t.co/Gaw6N6Z4Yk
-
-
Mashup Score: 1Express Delivery of Next-Generation CAR T Cells with Preserved Naive and Stemness Phenotypes for the Treatment of Aggressive Lymphomas - 8 month(s) ago
Summary:. In this issue of Cancer Discovery, Dickinson and colleagues present clinical data from a first-in-human study of YTB323, a novel autologous CD19-directed chimeric antigen receptor T-cell therapy generated on the T-Charge platform with preserved naive state and stemness phenotypes. Treatment with YTB323 achieved high overall response rates, durable complete remissions, and good overall safety. Their cell doses are up to 25-fold lower than with tisagenlecleucel.See related article by Dickinson et al., p. 1982 (10).
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the Spotlight: Express delivery of next-generation #CARTcells with preserved naïve and stemness phenotypes for the treatment of aggressive #lymphomas, by @michaelwangmd. https://t.co/v1fAJUWMB2 @MDAndersonNews https://t.co/yeRJ7vf9C0
-
-
Mashup Score: 0CAR T Cells: Engineering Immune Cells to Treat Cancer - 8 month(s) ago
Research on CAR T-cell therapy is progressing rapidly to improve the cancer treatment, expand its use to more cancers, and better manage its side effects.
Source: www.cancer.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Over the past decade, #immunotherapy has rapidly become what many call the "fifth pillar" of cancer treatment. Check out our updated summary on CAR T cells. https://t.co/qhZMA5dHSr #CARTcells
-
-
Mashup Score: 1Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors - 8 month(s) ago
Small extracellular vesicles secreted by solid tumors inhibit CAR T cells, which provide a molecular explanation for CAR T-cell resistance and suggests that strategies targeting exosome secretion may enhance CAR T-cell efficacy.
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
From the most recent issue— Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of #CARTCells against Solid Tumors, by Zhong et al. https://t.co/GOnZ9sQG29 @Penn_CBIO https://t.co/eXnfi30zFU
-
-
Mashup Score: 0Cyclosporine impact on tolerance induction after allo-HCT - 9 month(s) ago
Senjo H, Harada S, Kubota SI, et al. Calcineurin Inhibitor Inhibits Tolerance Induction by Suppressing Terminal Exhaustion of Donor T Cells After Allo-HCT. Blood. 2023; (doi:…
Source: nucleus.astct.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Researchers may have uncovered why, despite routine prophylaxis, many #alloHCT recipients fail to attain long-term tolerance w/o development of chronic #GVHD, and it has to do with transitory-tex and terminally-tex T cells. Read more on Nucleus: https://t.co/fN4HklI9Je #CARTcells https://t.co/RMEhTBKflg
-
-
Mashup Score: 1CD19-CAR T-Cell Therapy Demonstrates Activity Against Extramedullary Disease in Pediatric Patients with B-ALL - 9 month(s) ago
Key Points. There is a high burden of extramedullary disease in pediatric patients with relapsed/refractory B-ALL prior to CD19-CAR T cell therapyCD19-CAR T cel
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CD19-CAR T-Cell Therapy Demonstrates Activity Against Extramedullary Disease in Pediatric Patients with B-ALL https://t.co/UqsAISMtv8 #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy @BloodAdvances
-
-
Mashup Score: 2Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions - 9 month(s) ago
Key Points. In this analysis, checkpoint inhibitor therapy after CAR-T failure resulted in an overall response rate of 19% and median PFS of 54 days.Patients wi
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions https://t.co/UuYaPTw41z #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy @BloodAdvances https://t.co/dxIqLAQglA
-
-
Mashup Score: 4Emapalumab for the treatment of Refractory Cytokine Release Syndrome in Pediatric Patients - 9 month(s) ago
Emapalumab is a monoclonal antibody targeting interferon gamma (IFN-g) and is currently FDA-approved for refractory, recurrent, or progressive hemophagocytic ly
Source: ashpublications.orgCategories: Hematologists1, Latest HeadlinesTweet-
RT @CARTTherapy: Emapalumab for the treatment of Refractory Cytokine Release Syndrome in Pediatric Patients https://t.co/CU2I3YVz5g #CART…
-
Emapalumab for the treatment of Refractory Cytokine Release Syndrome in Pediatric Patients https://t.co/CU2I3YVz5g #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy @BloodAdvances
-
-
Mashup Score: 1
Abstract. Patients with cancer demonstrate an increased vulnerability for infection and severe disease by SARS-CoV-2, the causative agent of COVID-19. Risk fact
Source: academic.oup.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
COVID-19 Vaccination in Patients With ... HSCT or CAR-T Therapy: Immune Response, Implications for the Future https://t.co/Gkti77cot0 @CART_Therapy #CART #bmtsm #CARTcell #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CARTTherapy
-
COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy - Kampouri -#CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy https://t.co/k8fdrErKne